Drug Pricing ‘Opacity,’ Degrees Of Transparency Debated By National Academies Panel
Executive Summary
Second meeting of National Academies drug pricing committee was far-reaching discussion of several major themes, including PBM transparency, the political future for co-pay coupons and the next possible inflection point: the potential $1 million price tag for gene therapies.
You may also be interested in...
Who Wants To Be 'Essential'? US FDA Considers Critical Drugs List
To address chronic shortages, FDA may create list of 'essential' drugs, but will suppliers of those products be happy to be designated 'essential'?
Who Wants To Be 'Essential'? US FDA Considers Critical Drugs List
To address chronic shortages, FDA may create list of 'essential' drugs, but will suppliers of those products be happy to be designated 'essential'?
Mortgage-Style Payments For High-Cost Drugs Left On Cutting-Room Floor
NASEM's 'Making Medicines Affordable' report assembled a big package of recommendations (8), implementing actions (27), and findings (18), but the committee passed over one idea that might be important for curative treatments in the future.